$CABA
Cabaletta Bio, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061528 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.741M $4.880M
YoY Change 47.13% 37.0%
% of Gross Profit
Research & Development $17.41M $13.79M
YoY Change 40.36% 67.81%
% of Gross Profit
Depreciation & Amortization $336.0K $350.0K
YoY Change -6.15% -3.58%
% of Gross Profit
Operating Expenses $23.15M $18.67M
YoY Change 41.98% 58.5%
Operating Profit -$18.67M
YoY Change 58.5%
Interest Expense $2.260M $2.220M
YoY Change 270.49% 532.48%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.89M -$16.45M
YoY Change 33.1% 43.96%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.89M -$16.45M
YoY Change 33.1% 43.94%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.46 -$0.37
COMMON SHARES
Basic Shares Outstanding 42.85M 39.81M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.2M $164.4M
YoY Change 126.42% 91.4%
Cash & Equivalents $193.2M $115.5M
Short-Term Investments $48.01M $48.90M
Other Short-Term Assets $3.241M $1.800M
YoY Change 41.71% -21.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $244.5M $166.2M
YoY Change 124.64% 88.46%
LONG-TERM ASSETS
Property, Plant & Equipment $7.451M $1.990M
YoY Change 189.02% -29.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.709M $984.0K
YoY Change 202.48% 42.82%
Total Long-Term Assets $9.160M $7.109M
YoY Change 12.61% 103.11%
TOTAL ASSETS
Total Short-Term Assets $244.5M $166.2M
Total Long-Term Assets $9.160M $7.109M
Total Assets $253.7M $173.3M
YoY Change 116.85% 89.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.547M $3.620M
YoY Change 84.61% 171.57%
Accrued Expenses $8.760M $5.600M
YoY Change 53.85% 146.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.99M $10.62M
YoY Change 68.55% 83.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.458M $1.700M
YoY Change -50.73%
Total Long-Term Liabilities $1.458M $1.700M
YoY Change -50.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.99M $10.62M
Total Long-Term Liabilities $1.458M $1.700M
Total Liabilities $17.45M $12.36M
YoY Change 40.2% 113.14%
SHAREHOLDERS EQUITY
Retained Earnings -$233.2M -$212.4M
YoY Change 40.88% 41.69%
Common Stock $469.4M $373.3M
YoY Change 73.77% 58.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $236.2M $160.9M
YoY Change
Total Liabilities & Shareholders Equity $253.7M $173.3M
YoY Change 116.85% 89.02%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$20.89M -$16.45M
YoY Change 33.1% 43.94%
Depreciation, Depletion And Amortization $336.0K $350.0K
YoY Change -6.15% -3.58%
Cash From Operating Activities -$16.45M -$12.60M
YoY Change 35.59% 27.09%
INVESTING ACTIVITIES
Capital Expenditures $185.0K $60.00K
YoY Change -41.46% -105.49%
Acquisitions
YoY Change
Other Investing Activities $1.321M $0.00
YoY Change -100.0%
Cash From Investing Activities $1.136M -$70.00K
YoY Change -459.49% -100.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 93.05M 100.0K
YoY Change 182.9%
NET CHANGE
Cash From Operating Activities -16.45M -12.60M
Cash From Investing Activities 1.136M -70.00K
Cash From Financing Activities 93.05M 100.0K
Net Change In Cash 77.74M -12.57M
YoY Change 280.24% -189.82%
FREE CASH FLOW
Cash From Operating Activities -$16.45M -$12.60M
Capital Expenditures $185.0K $60.00K
Free Cash Flow -$16.63M -$12.66M
YoY Change 33.63% 43.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001759138
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39103
dei Entity Registrant Name
EntityRegistrantName
CABALETTA BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1685768
dei Entity Address Address Line1
EntityAddressAddressLine1
2929 Arch Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19104
dei Entity Address City Or Town
EntityAddressCityOrTown
Philadelphia
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
759-3100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
CABA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42849412
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115501000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81607000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
48890000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
24940000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1787000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2287000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
166178000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
108834000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1990000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2578000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4135000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4991000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
984000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
565000
CY2023Q3 us-gaap Assets
Assets
173287000
CY2022Q4 us-gaap Assets
Assets
116968000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3620000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2463000
CY2023Q3 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4474000
CY2022Q4 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4847000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2522000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2179000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10616000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9489000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1748000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2959000
CY2023Q3 us-gaap Liabilities
Liabilities
12364000
CY2022Q4 us-gaap Liabilities
Liabilities
12448000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41660169
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41660169
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29445134
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29445134
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373295000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
270129000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212351000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165562000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
160923000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
104520000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
173287000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116968000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13787000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8216000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38019000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26900000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4881000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3562000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13495000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10937000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
18668000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11778000
us-gaap Operating Expenses
OperatingExpenses
51514000
us-gaap Operating Expenses
OperatingExpenses
37837000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18668000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11778000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51514000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37837000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2220000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
351000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4725000
us-gaap Investment Income Interest
InvestmentIncomeInterest
554000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16448000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11427000
us-gaap Net Income Loss
NetIncomeLoss
-46789000
us-gaap Net Income Loss
NetIncomeLoss
-37283000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-18000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
40000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-21000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-209000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16466000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11387000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46810000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37492000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
117956000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1811000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-152000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12946000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
106720000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1777000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-97000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
40000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12910000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
95530000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1731000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
40000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11427000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
85874000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
104520000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2480000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
47000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
458000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15854000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
91651000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2803000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93755000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
390000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
32000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-3000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-14487000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
174141000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3009000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-18000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
239000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16448000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
160923000
us-gaap Profit Loss
ProfitLoss
-46789000
us-gaap Profit Loss
ProfitLoss
-37283000
us-gaap Share Based Compensation
ShareBasedCompensation
8292000
us-gaap Share Based Compensation
ShareBasedCompensation
5319000
us-gaap Depreciation
Depreciation
1090000
us-gaap Depreciation
Depreciation
820000
caba Non Cash Lease Expense
NonCashLeaseExpense
1410000
caba Non Cash Lease Expense
NonCashLeaseExpense
0
us-gaap Accretion Expense
AccretionExpense
288000
us-gaap Accretion Expense
AccretionExpense
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
839000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
177000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
420000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
332000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1157000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1055000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-81000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1580000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1709000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37101000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34249000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
502000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2137000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
48085000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49764000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
25000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
25000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23587000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26901000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93463000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1087000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
32000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
40000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94582000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
33894000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-61059000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81607000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122222000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115501000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61163000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
554000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
191000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
164391000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212351000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
164412000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, the valuation allowance on the Company’s deferred tax assets and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
164391000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106594000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106547000
CY2023Q3 caba Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
1062000
CY2022Q4 caba Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
1194000
CY2023Q3 caba Accrued General And Administrative Services Current
AccruedGeneralAndAdministrativeServicesCurrent
272000
CY2022Q4 caba Accrued General And Administrative Services Current
AccruedGeneralAndAdministrativeServicesCurrent
99000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3110000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3515000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
30000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39000
CY2023Q3 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4474000
CY2022Q4 caba Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4847000
CY2023Q3 caba Upfront Payment
UpfrontPayment
500
CY2023Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
us-gaap Lease Cost
LeaseCost
2245000
us-gaap Operating Lease Cost
OperatingLeaseCost
1697000
us-gaap Variable Lease Cost
VariableLeaseCost
50000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
498000
us-gaap Operating Lease Payments
OperatingLeasePayments
1709000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1127000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
674000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
2627000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1320000
CY2023Q3 caba Lessee Undiscounted Lease Payments
LesseeUndiscountedLeasePayments
4621000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
351000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4270000
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P18M
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2019Q4 us-gaap Common Stock Conversion Features
CommonStockConversionFeatures
Each share of the Company’s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company
caba Pre Funded Warrants Exercised
PreFundedWarrantsExercised
3868184
CY2023Q4 caba Addition In Pre Funded Warrants Exercised
AdditionInPreFundedWarrantsExercised
1177538
CY2023Q3 caba Shares Remaining Available For Issuance
SharesRemainingAvailableForIssuance
2926285
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0338
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0438
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0336
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26578000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2345592
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8198580
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6084284

Files In Submission

Name View Source Status
caba-20230930_def.xml Edgar Link unprocessable
0000950170-23-061528-index-headers.html Edgar Link pending
0000950170-23-061528-index.html Edgar Link pending
0000950170-23-061528.txt Edgar Link pending
0000950170-23-061528-xbrl.zip Edgar Link pending
caba-20230930.htm Edgar Link pending
caba-20230930.xsd Edgar Link pending
caba-ex10_1.htm Edgar Link pending
caba-ex10_2.htm Edgar Link pending
caba-ex31_1.htm Edgar Link pending
caba-ex31_2.htm Edgar Link pending
caba-ex32_1.htm Edgar Link pending
caba-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
caba-20230930_lab.xml Edgar Link unprocessable
caba-20230930_pre.xml Edgar Link unprocessable
caba-20230930_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
caba-20230930_cal.xml Edgar Link unprocessable